SCHEMBL26601774

SCHEMBL26601774

Cc1cc(C(C)(C)C)ccc1-c1cc(OCc2ccccc2)c(C=O)c(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
STAT3 P40763 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
AR P10275 3/20 0.39
RXRA P19793 2/20 0.37
RXRB P28702 2/20 0.37
RXRG P48443 2/20 0.37
TRPV1 Q8NER1 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601660 0.85 SMN1; SMN2 (0.48) MRGPRX4SMN1; SMN2STAT3HTTNPC1
SCHEMBL26601634 0.84 MRGPRX4 (0.43) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26601643 0.84 MRGPRX4 (0.43) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26601938 0.84 MRGPRX4 (0.43) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26706242 0.83 MRGPRX4 (0.39) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26601676 0.83 MRGPRX4 (0.51) MRGPRX4SMN1; SMN2STAT3HTTRAB9A
SCHEMBL31747877 0.82 MRGPRX4 (0.44) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26706194 0.82 MRGPRX4 (0.44) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26706913 0.81 MRGPRX4 (0.40) MRGPRX4SMN1; SMN2STAT3HTTMAPT
SCHEMBL26601626 0.80 MRGPRX4 (0.43) MRGPRX4SMN1; SMN2STAT3HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 MRGPRX4 999/4885SMN1; SMN2 760/4885STAT3 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.